TrialBreast cancer research and treatment2021

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.

Hope S Rugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.